{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:54:55Z","timestamp":1785858895647,"version":"3.56.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Pompe disease is an autosomal recessive genetic disease caused by a mutation in the acid \u03b1-glucosidase (GAA) gene, which results in dysfunction of the GAA and a buildup of glycogen in lysosomes. Recently, new research has found additional causes of the disease pathology, such as the role of autophagy. Currently, the standard of care is enzyme replacement therapy (ERT). ERT has been proven to increase survival in Pompe disease as well as improve pulmonary and motor tests compared to no treatment. However, some patients do not see improvement from these treatments, and the life expectancy and quality of life of patients with Pompe disease remain low. New research focuses on gene therapy with an adeno-associated virus-mediated \u03b1-glucosidase vector (rAAV1-hGAA or rAAV1-CMV-hGAA). Gene therapy has the potential to provide longer-term treatment for patients with Pompe disease. Patients commonly experience side effects from the procedure such as pneumothorax, capnothorax, pericardial effusion, pleural effusion, lung contusion, etc. In phase I\/II trials, the gene therapy has been found to be safe, result in sustained GAA levels, and have some improvements in pulmonary function. Many clinical trials are currently ongoing.<\/jats:p>","DOI":"10.1097\/crd.0000000000000980","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:01:31Z","timestamp":1751446891000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pompe Disease: Current State and Future Treatments"],"prefix":"10.1097","author":[{"given":"Margot","family":"Richards","sequence":"first","affiliation":[{"name":"New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"R1-20250702","first-page":"1","article-title":"Lysosomal storage diseases.","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250702","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbacli.2016.02.001","article-title":"Glycogen metabolism in humans.","volume":"5","author":"Adeva-Andany","year":"2016","journal-title":"BBA Clin"},{"key":"R3-20250702","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again.","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"R4-20250702","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/ijns6030055","article-title":"Establishing Pompe disease newborn screening: the role of industry.","volume":"6","author":"Keutzer","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"R5-20250702","first-page":"271","article-title":"Infantile-onset Pompe disease: diagnosis and management.","volume":"117","author":"Bay","year":"2019","journal-title":"Arch Argent Pediatr"},{"key":"R6-20250702","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis.","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"R7-20250702","first-page":"100929","article-title":"Newborn screening for Pompe disease in Italy: long-term results and future challenges.","volume":"33","author":"Gragnaniello","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"R9-20250702","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.","volume":"6","author":"G\u00fcng\u00f6r","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"R10-20250702","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"key":"R11-20250702","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease.","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"key":"R12-20250702","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","article-title":"The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients.","volume":"35","author":"Van Capelle","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"R13-20250702","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/cells11030334","article-title":"Six-minute walk distance is a useful outcome measure to detect motor decline in treated late-onset Pompe disease patients.","volume":"11","author":"Claeys","year":"2022","journal-title":"Cells"},{"key":"R14-20250702","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/j.nmd.2015.06.029","article-title":"Lung function tests (MIP, MEP, FVC, VC) predict ventilation and wheelchair use in late-onset Pompe disease.","volume":"25","author":"Roberts","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"R15-20250702","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"R16-20250702","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/14712598.2022.2067476","article-title":"What\u2019s new and what\u2019s next for gene therapy in Pompe disease?","volume":"22","author":"Roger","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"R17-20250702","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.nmd.2008.04.010","article-title":"Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle.","volume":"18","author":"Malicdan","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"R18-20250702","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/acn3.50800","article-title":"Identification of serum microRNAs as potential biomarkers in Pompe disease.","volume":"6","author":"Carrasco-Rozas","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"R19-20250702","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype\u2013phenotype correlation in Pompe disease.","volume":"160C","author":"Kroos","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R20-20250702","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1038\/s41598-023-33543-y","article-title":"Degeneration of muscle spindles in a murine model of Pompe disease.","volume":"13","author":"Watkins","year":"2023","journal-title":"Sci Rep"},{"key":"R21-20250702","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.31317","article-title":"Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten.","volume":"160C","author":"Raben","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R22-20250702","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers: \u201cto see a world in a grain of sand\u2026.\u201d.","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"key":"R23-20250702","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2051-5960-2-2","article-title":"The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients.","volume":"2","author":"Feeney","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"R24-20250702","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijcard.2023.03.010","article-title":"Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease.","volume":"380","author":"Scheffers","year":"2023","journal-title":"Int J Cardiol"},{"key":"R25-20250702","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.gim.0000195896.04069.5f","article-title":"Electrocardiographic response to enzyme replacement therapy for Pompe disease.","volume":"8","author":"Ansong","year":"2006","journal-title":"Genet Med"},{"key":"R26-20250702","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2018.07.091","article-title":"Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.","volume":"269","author":"Van Capelle","year":"2018","journal-title":"Int J Cardiol"},{"key":"R27-20250702","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/GIM.0b013e3182142966","article-title":"Cardiovascular abnormalities in late onset Pompe disease and response to enzyme replacement therapy.","volume":"13","author":"Forsha","year":"2011","journal-title":"Genet Med"},{"key":"R28-20250702","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCGENETICS.115.001322","article-title":"Elevated plasma cardiac troponin t levels caused by skeletal muscle damage in Pompe disease.","volume":"9","author":"Wens","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"R29-20250702","first-page":"615","article-title":"Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe\u2019s disease treated with recombinant alpha-glucosidase.","volume":"52","author":"Hahn","year":"2006","journal-title":"Clin Lab"},{"key":"R30-20250702","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline.","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"R31-20250702","first-page":"82","article-title":"Clinical features of Pompe disease.","volume":"32","author":"Manganelli","year":"2013","journal-title":"Acta Myol"},{"key":"R32-20250702","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00415-006-0434-2","article-title":"Fatigue: an important feature of late-onset Pompe disease.","volume":"254","author":"Hagemans","year":"2007","journal-title":"J Neurol"},{"key":"R33-20250702","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","article-title":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.","volume":"119","author":"van der Ploeg","year":"2016","journal-title":"Mol Genet Metab"},{"key":"R34-20250702","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.","volume":"22","author":"Khan","year":"2020","journal-title":"Genet Med"},{"key":"R35-20250702","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-023-02981-2","article-title":"Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (Iopd): data from the Pompe registry.","volume":"18","author":"Kishnani","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"R36-20250702","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1017\/S1047951121002079","article-title":"Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort.","volume":"32","author":"Byrne","year":"2022","journal-title":"Cardiol Young"},{"key":"R37-20250702","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/gim.2018.2","article-title":"Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.","volume":"20","author":"Hahn","year":"2018","journal-title":"Genet Med"},{"key":"R38-20250702","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (Comet): a phase 3, randomised, multicentre trial.","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"key":"R39-20250702","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report.","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet Med"},{"key":"R40-20250702","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks.","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol"},{"key":"R41-20250702","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-017-0693-2","article-title":"A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.","volume":"12","author":"Byrne","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"R42-20250702","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of biochemical abnormalities and improved muscle function in a phase I\/II clinical trial of clenbuterol in Pompe disease.","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol Ther"},{"key":"R43-20250702","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease.","volume":"31","author":"Smith","year":"2023","journal-title":"Mol Ther"},{"key":"R44-20250702","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes.","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"key":"R45-20250702","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease.","volume":"28","author":"Corti","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"Pt 2","key":"R46-20250702","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","article-title":"Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity.","volume":"287","author":"Smith","year":"2017","journal-title":"Exp Neurol"},{"key":"R47-20250702","doi-asserted-by":"crossref","first-page":"eadf1691","DOI":"10.1126\/scitranslmed.adf1691","article-title":"Small molecule inhibition of glycogen synthase I for the treatment of Pompe disease and other glycogen storage disorders.","volume":"16","author":"Ullman","year":"2024","journal-title":"Sci Transl Med"},{"key":"R48-20250702","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study.","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"R49-20250702","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"R50-20250702","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2017.12.435","article-title":"Enzyme replacement therapy with alglucosidase alfa in Pompe disease: clinical experience with rate escalation.","volume":"123","author":"Desai","year":"2018","journal-title":"Mol Genet Metab"},{"key":"R51-20250702","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"R52-20250702","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s00415-021-10475-z","article-title":"The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.","volume":"268","author":"Wenninger","year":"2021","journal-title":"J Neurol"},{"key":"R53-20250702","doi-asserted-by":"crossref","first-page":"282","DOI":"10.21037\/atm.2019.05.52","article-title":"Nutrition and exercise in Pompe disease.","volume":"7","author":"Tarnopolsky","year":"2019","journal-title":"Ann Transl Med"},{"key":"R54-20250702","first-page":"1","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases.","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"R55-20250702","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (Aav) as a vector for gene therapy.","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"R56-20250702","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cytogfr.2024.09.003","article-title":"Adeno-associated virus therapies: pioneering solutions for human genetic diseases.","volume":"80","author":"Liu","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"R57-20250702","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches.","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum Gene Ther"},{"key":"R58-20250702","doi-asserted-by":"crossref","first-page":"666666","DOI":"10.3389\/fimmu.2021.666666","article-title":"T cell-mediated immune responses to aav and aav vectors.","volume":"12","author":"Ertl","year":"2021","journal-title":"Front Immunol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:59:10Z","timestamp":1785855550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000980","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}